Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease
Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease
NCT ID: NCT00566501 Phase: PHASE3 Status: COMPLETED Enrollment: 915 Completion: 2010-04-01
Conditions
Alzheimer's Disease
Interventions
Donepezil
Summary
The purpose of this study is to evaluate the safety and efficacy of long-term administration of 23 milligram (mg) donepezil sustained release (SR) in participants with moderate to severe Alzheimer's disease. Participants who complete study E2020-G000-326 (NCT00478205) with no ongoing serious adverse events (SAEs) and no serious adverse drug reactions will be eligible to enter the open-label extension study.
Primary Outcome
Number of Participants With Adverse Events (AEs)